These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19663790)

  • 41. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
    Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
    Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
    Biron E; Bédard F
    J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription.
    Féau C; Arnold LA; Kosinski A; Zhu F; Connelly M; Guy RK
    ACS Chem Biol; 2009 Oct; 4(10):834-43. PubMed ID: 19645433
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
    Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
    Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Curcumin-based anti-prostate cancer agents.
    Chen QH
    Anticancer Agents Med Chem; 2015; 15(2):138-56. PubMed ID: 25594891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice.
    Narayanan NK; Nargi D; Randolph C; Narayanan BA
    Int J Cancer; 2009 Jul; 125(1):1-8. PubMed ID: 19326431
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
    Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
    Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells.
    Chung LC; Tsui KH; Feng TH; Lee SL; Chang PL; Juang HH
    Mol Nutr Food Res; 2011 Nov; 55(11):1666-76. PubMed ID: 21936051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents.
    Lin L; Shi Q; Su CY; Shih CC; Lee KH
    Bioorg Med Chem; 2006 Apr; 14(8):2527-34. PubMed ID: 16427289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modification of androgen receptor function by IGF-1 signaling implications in the mechanism of refractory prostate carcinoma.
    Yanase T; Fan W
    Vitam Horm; 2009; 80():649-66. PubMed ID: 19251054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis, and biological evaluation of 1,9-diheteroarylnona-1,3,6,8-tetraen-5-ones as a new class of anti-prostate cancer agents.
    Zhang X; Wang R; Perez GR; Chen G; Zhang Q; Zheng S; Wang G; Chen QH
    Bioorg Med Chem; 2016 Oct; 24(19):4692-4700. PubMed ID: 27543391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate.
    Wang LG; Liu XM; Chiao JW
    Carcinogenesis; 2006 Oct; 27(10):2124-32. PubMed ID: 16704988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
    Fernández-Martínez AB; Bajo AM; Valdehita A; Isabel Arenas M; Sánchez-Chapado M; Carmena MJ; Prieto JC
    Peptides; 2009 Dec; 30(12):2357-64. PubMed ID: 19772879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Redox nanoparticles inhibit curcumin oxidative degradation and enhance its therapeutic effect on prostate cancer.
    Thangavel S; Yoshitomi T; Sakharkar MK; Nagasaki Y
    J Control Release; 2015 Jul; 209():110-9. PubMed ID: 25912409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.